Quality of Life After Deep Brain Stimulation of Pediatric Patients with Dyskinetic Cerebral Palsy: A Prospective, Single-Arm, Multicenter Study with a Subsequent Randomized Double-Blind Crossover (STIM-CP).
children
deep brain stimulation
dyskinetic cerebral palsy
prospective trial; quality of life
Journal
Movement disorders : official journal of the Movement Disorder Society
ISSN: 1531-8257
Titre abrégé: Mov Disord
Pays: United States
ID NLM: 8610688
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
revised:
05
11
2021
received:
10
09
2021
accepted:
08
12
2021
pubmed:
31
12
2021
medline:
20
4
2022
entrez:
30
12
2021
Statut:
ppublish
Résumé
Patients with dyskinetic cerebral palsy are often severely impaired with limited treatment options. The effects of deep brain stimulation (DBS) are less pronounced than those in inherited dystonia but can be associated with favorable quality of life outcomes even in patients without changes in dystonia severity. The aim is to assess DBS effects in pediatric patients with pharmacorefractory dyskinetic cerebral palsy with focus on quality of life. The method used is a prospective, single-arm, multicenter study. The primary endpoint is improvement in quality of life (CPCHILD [Caregiver Priorities & Child Health Index of Life with Disabilities]) from baseline to 12 months under therapeutic stimulation. The main key secondary outcomes are changes in Burke-Fahn-Marsden Dystonia Rating Scale, Dyskinesia Impairment Scale, Gross Motor Function Measure-66, Canadian Occupational Performance Measure (COPM), and Short-Form (SF)-36. After 12 months, patients were randomly assigned to a blinded crossover to receive active or sham stimulation for 24 hours each. Severity of dystonia and chorea were blindly rated. Safety was assessed throughout. The trial was registered at ClinicalTrials.gov, number NCT02097693. Sixteen patients (age: 13.4 ± 2.9 years) were recruited by seven clinical sites. Primary outcome at 12-month follow-up is as follows: mean CPCHILD increased by 4.2 ± 10.4 points (95% CI [confidence interval] -1.3 to 9.7; P = 0.125); among secondary outcomes: improvement in COPM performance measure of 1.1 ± 1.5 points (95% CI 0.2 to 1.9; P = 0.02) and in the SF-36 physical health component by 5.1 ± 6.2 points (95% CI 0.7 to 9.6; P = 0.028). Otherwise, there are no significant changes. Evidence to recommend DBS as routine treatment to improve quality of life in pediatric patients with dyskinetic cerebral palsy is not yet sufficient. Extended follow-up in larger cohorts will determine the impact of DBS further to guide treatment decisions in these often severely disabled patients. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Sections du résumé
BACKGROUND
Patients with dyskinetic cerebral palsy are often severely impaired with limited treatment options. The effects of deep brain stimulation (DBS) are less pronounced than those in inherited dystonia but can be associated with favorable quality of life outcomes even in patients without changes in dystonia severity.
OBJECTIVE
The aim is to assess DBS effects in pediatric patients with pharmacorefractory dyskinetic cerebral palsy with focus on quality of life.
METHODS
The method used is a prospective, single-arm, multicenter study. The primary endpoint is improvement in quality of life (CPCHILD [Caregiver Priorities & Child Health Index of Life with Disabilities]) from baseline to 12 months under therapeutic stimulation. The main key secondary outcomes are changes in Burke-Fahn-Marsden Dystonia Rating Scale, Dyskinesia Impairment Scale, Gross Motor Function Measure-66, Canadian Occupational Performance Measure (COPM), and Short-Form (SF)-36. After 12 months, patients were randomly assigned to a blinded crossover to receive active or sham stimulation for 24 hours each. Severity of dystonia and chorea were blindly rated. Safety was assessed throughout. The trial was registered at ClinicalTrials.gov, number NCT02097693.
RESULTS
Sixteen patients (age: 13.4 ± 2.9 years) were recruited by seven clinical sites. Primary outcome at 12-month follow-up is as follows: mean CPCHILD increased by 4.2 ± 10.4 points (95% CI [confidence interval] -1.3 to 9.7; P = 0.125); among secondary outcomes: improvement in COPM performance measure of 1.1 ± 1.5 points (95% CI 0.2 to 1.9; P = 0.02) and in the SF-36 physical health component by 5.1 ± 6.2 points (95% CI 0.7 to 9.6; P = 0.028). Otherwise, there are no significant changes.
CONCLUSION
Evidence to recommend DBS as routine treatment to improve quality of life in pediatric patients with dyskinetic cerebral palsy is not yet sufficient. Extended follow-up in larger cohorts will determine the impact of DBS further to guide treatment decisions in these often severely disabled patients. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Banques de données
ClinicalTrials.gov
['NCT02097693']
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
799-811Informations de copyright
© 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Références
Sellier E, Platt MJ, Andersen GL, Krageloh-Mann I, De La Cruz J, Cans C. Decreasing prevalence in cerebral palsy: a multi-site European population-based study, 1980 to 2003. Dev Med Child Neurol 2016;58(1):85-92.
Monbaliu E, Himmelmann K, Lin JP, et al. Clinical presentation and management of dyskinetic cerebral palsy. Lancet Neurol 2017;16(9):741-749.
Koy A, Lin JP, Sanger TD, et al. Advances in management of movement disorders in children. Lancet Neurol 2016;15(7):719-735.
Volkmann J, Wolters A, Kupsch A, et al. Pallidal deep brain stimulation in patients with primary generalised or segmental dystonia: 5-year follow-up of a randomised trial. Lancet Neurol 2012;11(12):1029-1038.
Koy A, Hellmich M, Pauls KA, et al. Effects of deep brain stimulation in dyskinetic cerebral palsy: a meta-analysis. Mov Disord 2013;28(5):647-654.
Vidailhet M, Yelnik J, Lagrange C, et al. Bilateral pallidal deep brain stimulation for the treatment of patients with dystonia-choreoathetosis cerebral palsy: a prospective pilot study. Lancet Neurol 2009;8(8):709-717.
Elia AE, Bagella CF, Ferre F, Zorzi G, Calandrella D, Romito LM. Deep brain stimulation for dystonia due to cerebral palsy: a review. Eur J Paediatr Neurol 2018;22(2):308-315.
Gimeno H, Tustin K, Selway R, Lin JP. Beyond the Burke-Fahn-Marsden dystonia rating scale: deep brain stimulation in childhood secondary dystonia. Eur J Paediatr Neurol 2012;16(5):501-508.
Koy A, Kühn AA, van Riesen A, et al. Effect of deep brain stimulation of the Globus pallidus internus on quality of life in young patients with Dyskinetic cerebral palsy (STIMCP): a prospective single-arm multicenter trial with a double-blind cross-over at 12-months follow-up. J Clin Trials 2017;7(4):1-9.
Narayanan UG, Fehlings D, Weir S, Knights S, Kiran S, Campbell K. Initial development and validation of the caregiver priorities and child health index of life with disabilities (CPCHILD). Dev Med Child Neurol 2006;48(10):804-812.
Murphy AM, Milo-Manson G, Best A, Campbell KA, Fehlings D. Impact of modafinil on spasticity reduction and quality of life in children with CP. Dev Med Child Neurol 2008;50(7):510-514.
Hill M, Armitage P. The two-period cross-over clinical trial. Br J Clin Pharmacol 1979;8:7-20.
Sanger TD. Deep brain stimulation for cerebral palsy: where are we now? Dev Med Child Neurol 2020;62(1):28-33.
Krageloh-Mann I, Helber A, Mader I, et al. Bilateral lesions of thalamus and basal ganglia: origin and outcome. Dev Med Child Neurol 2002;44(7):477-484.
Quartarone A, Hallett M. Emerging concepts in the physiological basis of dystonia. Mov Disord 2013;28(7):958-967.
McClelland VM, Fiahlo D, Flexney-Briscoe D, et al. Somatosensory evoked potentials and central motor conduction times in children with dystonia and their correlation with outcomes from deep brain stimulation of the Globus pallidus internus. Clin Neurophysiol 2018 Feb;129(2):473-486.
Lin JP, Lumsden DE, Gimeno H, Kaminska M. The impact and prognosis for dystonia in childhood including dystonic cerebral palsy: a clinical and demographic tertiary cohort study. J Neurol Neurosurg Psychiatr 2014;85(11):1239-1244.
Lumsden DE, Kaminska M, Gimeno H, et al. Proportion of life lived with dystonia inversely correlates with response to pallidal deep brain stimulation in both primary and secondary childhood dystonia. Dev Med Child Neurol 2013;55(6):567-574.
Haberfehlner H, Goudriaan M, Bonouvrié LA, et al. Instrumented assessment of motor function in dyskinetic cerebral palsy: a systematic review. J Neuroeng Rehabil 2020;17(1):39
Burke RE, Fahn S, Marsden CD, Bressman SB, Moskowitz C, Friedman J. Validity and reliability of a rating scale for the primary torsion dystonias. Neurology 1985;35(1):73-77.
Tustin K, Elze MC, Lumsden DE, Gimeno H, Kaminska M, Lin JP. Gross motor function outcomes following deep brain stimulation for childhood-onset dystonia: a descriptive report. Eur J Paediatr Neurol 2019;23(3):473-83.21.
Lumsden DE, Gimeno H, Tustin K, Kaminska K, Lin JP. Interventional studies in childhood dystonia do not address the concerns of children and their carers. Eur J Pediatr Neurol 2017;21(1):147-167.
Gimeno H, Lin JP. The international classification of functioning (ICF) to evaluate deep brain stimulation neuromodulation in childhood dystonia-hyperkinesia informs future clinical & research priorities in a multidisciplinary model of care. Eur J Paediatr Neurol 2017;21(1):147-167.
Gimeno H, Tustin K, Lumsden D, Ashkan K, Selway R, Lin JP. Evaluation of functional goal outcomes using the Canadian occupational performance measure (COPM) following deep brain stimulation (DBS) in childhood dystonia. Eur J Paediatr Neurol 2014;18(3):308-316.
Kaminska M, Perides S, Lumsden DE, et al. Complications of deep brain stimulation (DBS) for dystonia in children - the challenges and 10 year experience in a large paediatric cohort. Eur J Paediatr Neurol 2017;21(1):168-175.
Air EL, Ostrem JL, Sanger TD, Starr PA. Deep brain stimulation in children: experience and technical pearls. J Neurosurg Pediatr 2011;8(6):566-574.
Ismail FY, Fatemi A, Johnston MV. Cerebral plasticity: windows of opportunity in the developing brain. Eur J Paediatr Neurol 2017;21(1):23-48.
Lumsden DE, Kaminska M, Tomlin S, Lin JP. Medication use in childhood dystonia. Eur J Paediatr Neurol 2016;20(4):625-629.
Ruge D, Cif L, Limousin P, et al. Longterm deep brain stimulation withdrawal: clinical stability despite electrophysiological instability. J Neurol Sci 2014;342(1-2):197-199.
Romito LM, Zorzi G, Marras CE, Franzini A, Nardocci N, Albanese A. Pallidal stimulation for acquired dystonia due to cerebral palsy: beyond 5 years. Eur J Neurol 2015;22(3):426-e32.
Koy A, Weinsheimer M, Pauls KA, et al. German registry of paediatric deep brain stimulation in patients with childhood-onset dystonia (GEPESTIM). Eur J Paediatr Neurol 2017;21(1):136-146.
Marks W, Bailey L, Sanger TD. PEDiDBS: the pediatric international deep brain stimulation registry project. Eur J Paediatr Neurol 2017;21(1):218-222.